Generally speaking, a better deal than I anticipated
It provides a small window of opportunity for Oncolix to gain traction with their clinicals and raise a little more $$ which places Oncolix in a much better position than they were a week ago
Next, Oncolix needs to let investors know what's going on with the 2nd cohort... meaning, how many are being or have been dosed, etc, etc